Candlelites

Everything from Everywhere

fda approves first drug for women with breast cancer caused by flawed inherited gene

fda approves first drug for women with breast cancer caused by flawed inherited gene News Article With The full text news. The Resource Link is down the post and you can View this News Article in the source page.



fda approves first drug for women with breast cancer caused by flawed inherited gene

u.s. regulators have approved the first drug aimed at women with advanced breast cancer caused byan inherited flawed gene.the food and drug administration on friday approved astrazeneca plc's lynparza for patients with inherited brca gene mutations who have had chemotherapy.the drug has been on the market since 2014 for ovarian cancer, and is the first in a new class of medicines called parp inhibitors to be approved for breast cancer. parp inhibitors prevent cancer cells from fixing problems in their dna.lynparza will cost $13,886 per month without insurance, according to astrazeneca. the company is offering patients financial assistance."while there is currently no cure for metastatic breast cancer, today's approval offers a new, targeted option that may help to delay disease progression for these patients," said dr. susan domchek of the university of pennsylvania's abramson cancer center.until recently, cancer medicines targeted the disease based on where in the body it occurs. this is a new approach to "target the underlying genetic causes of a cancer," the fda's dr. richard pazdur said in a statement.the agency also approved a companion blood test from myriad genetic laboratories inc. for detecting brca mutations and determining which patients likely would benefit from lynparza.about 250,000 people each year are diagnosed with breast cancer and just over 40,000 die from it, according to the national cancer institute. about 20 to 25 percent of patients with heredi...